Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

Edinburgh BioQuarter appoints commercialisation director

March 16, 2010 Research and Development Edinburgh BioQuarter, appointment, research and development

Dr Michael Capaldi has joined Scottish life sciences research hub Edinburgh BioQuarter as director of commercialisation. He will lead a …
Appointment
GSKstephenne

GSK promotes Jean Stephenne to chairman, biologicals

March 15, 2010 Research and Development, Sales and Marketing GlaxoSmithKline, appointment, research and development, sales and marketing

GlaxoSmithKline has appointed Jean Stephenne chairman of GSK Biologicals, the company’s global vaccines division.He is currently president and general manager of …
Appointment

Contract research news in brief

March 15, 2010 Research and Development Bilcare, CRO, Kendle, Lonza, Medidata, Melbourn, Quintiles, RDNIB

Our round-up of developments in the contract research sector includes updates from Kendle, Bilcare, Quintiles, Melbourn Scientific, Lonza, and Medidata …
News

Pfizer suffers late-stage cancer drug failures

March 12, 2010 Research and Development Cancer, Pfizer, Sutent, figitumumab

Pfizer has suffered late-stage trial failures for Sutent and lung cancer candidate figitumumab. Kidney cancer drug Sutent (sunitinib) failed to …
News

GSK expands inflammatory alliance

March 12, 2010 Research and Development Cellzome, GlaxoSmithKline, rheumatoid arthritis

GlaxoSmithKline has formed a second strategic alliance with Cellzome to research new treatments for inflammatory diseases. GSK will buy into …
News

Novartis buys into Transgene’s lung cancer candidate

March 11, 2010 Research and Development Novartis, Transgene, immunotherapy, lung cancer

French biotech company Transgene has signed a deal with Novartis for the future development and marketing of its potential lung …
News

Investments boost Irish pharma sector

March 11, 2010 Research and Development, Sales and Marketing Ireland, PPD, Warner Chilcott

Contract research organisation PPD has officially opened its new research laboratory in Athlone, Ireland, and started recruiting for the first …
News

Five-year cardiovascular study planned for Onglyza

March 10, 2010 Research and Development, Sales and Marketing DPP-4, Onglyza, diabetes

Bristol-Myers Squibb and AstraZeneca are to embark on a five-year study of Onglyza in type II diabetes patients who may …
News

Abbott boosts pipeline with biotech acquisition

March 10, 2010 Research and Development, Sales and Marketing Abbott, Facet Biotech, daclizumab, volociximab

Abbott is to acquire US company Facet Biotech in a $450 million deal that will boost its oncology and immunology …
News
Worker protest

GSK Italy workers protest site closure

March 10, 2010 Research and Development GlaxoSmithKline, Italy, job cuts

Workers at a GlaxoSmithKline R&D facility in Verona, Italy, have taken to the streets to protest a decision to close …
News

Recentin disappoints in colorectal cancer

March 9, 2010 Research and Development AZ, Cancer, Recentin, colorectal cancer

AstraZeneca’s developmental oncology drug Recentin has failed to meet its primary endpoint in a phase II/III study. The once-daily oral …
News

Pfizer and King’s to collaborate on pain research

March 9, 2010 Research and Development King's, Pfizer, UK

Pfizer has partnered with King’s College London to create an open innovation laboratory for pain research.The project will include a …
News
Rheumatoid arthritis

Roche halts ocrelizumab trials

March 8, 2010 Research and Development RoActemra, ocrelizumab, rheumatoid arthritis

The future of Roche and Biogen Idec’s rheumatoid arthritis drug ocrelizumab has been thrown into doubt after the manufacturers decided …
News
Blood clot

Phase III success for apixaban

March 5, 2010 Research and Development BMS, Pfizer, VTE, apixaban

Pfizer and Bristol-Myers Squibb’s apixaban has shown promising results in a late-stage head-to-head trial with Sanofi-Aventis’ Lovenox. The oral anti-coagulant …
News

Pfizer suffers Alzheimer’s setback

March 4, 2010 Research and Development Alzheimer's, Medivation, Pfizer

Pfizer has suffered a big setback with the oral Alzheimer’s disease treatment it is developing with biotech outfit Medivation. Investigational …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026